Uniqsis expands LED photoreactor range

3 Mar 2019

The availability of three new alternative switchable LED configurations provides chemists with the unique ability to optimally undertake almost any photochemistry reaction.

Uniqsis announces its PhotoSyn high-power photoreactor light module for continuous flow chemistry is now available with alternative LED array configurations that makes it compatible with a broader range of photochemical reactions.

Uniqsis expands LED photoreactor range

The availability of three new alternative switchable LED configurations (blue, UVA-blue and blue-green-white) provides chemists with the unique ability to optimally undertake almost any photochemistry reaction. The operating wavelengths of the three LED array configurations are blue (455 nm), blue-green-white (455 nm, 530 nm and 420-700 nm) and UVA-blue (365 nm and 455 nm).

The curved, water-cooled LED arrays in the PhotoSyn are designed to maximise photon intensity and concentrate the available light on the independently temperature controlled central coil reactor. These high-quality LED’s have lifetimes of several years in continuous use without suffering a significant reduction in intensities.

The PhotoSyn incorporates a cooling fan to minimise undesirable radiative heating of the flow reactor whilst being cleverly engineered to completely prevent potentially hazardous light emissions from the unit, thereby avoiding the need to operate the instrument in a shielded enclosure. Moreover, the PhotoSyn is protected with safety interlocks that deactivate the light source and protect the user if any attempt is made to remove the cover whilst in use.

The PhotoSyn is compatible with both the Uniqsis Cold Coil standalone reactor module and the Polar Bear Plus Flow cryogenic flow reactor, which control the coil reactor temperature independently of the lamps. Reactions may be run from 150 °C down to sub-ambient temperatures dependent upon the power of the cooling unit used. The variable power supply allows the lamp power output to be adjusted from 10-100% making the unit suitable for both small scale R&D and scale up applications.

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
World’s leading biobanks join a global network to advance personalized healthcare research

World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more